Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled.
Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
November 19, 2013, Session CS.03 American Heart Association Scientific Sessions, Dallas, TX
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with.
Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Roth,
Clinicaltrials no. NCT01288443
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J.
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo- Controlled.
Presenter Disclosure Information
